Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s Denosumab, GTx’s Toremifene Keep Pace At ASCO On Prevention Of Bone Fractures In Prostate Cancer Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Both firms have October user fee dates for prevention of bone fracture risk in prostate cancer patients on androgen deprivation therapy, and both report favorable incremental data.

You may also be interested in...



FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says

Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.

FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says

Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.

FDA "Complete Response" On Toremifene Moves The Goal Posts, GTx CEO Says

GTx was taken by surprise with FDA's decision to issue a "complete response" letter for the firm's selective estrogen receptor modulator toremifene 80 mg - a drug whose clinical development program was designed with the agency's help under a Special Protocol Assessment

Related Content

Topics

UsernamePublicRestriction

Register

PS069526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel